January 3, 2019 09:34 AM ESTUpdated May 26, 08:22 PM
R&D
Pharma
Cell/Gene Tx

Take­da builds ar­se­nal for im­muno-on­col­o­gy re­search, cre­ates cell ther­a­py group

Natalie Grover

Reporter

Take­da’s pres­ence in can­cer — for­ti­fied by its $5.2 bil­lion Ari­ad buy­out — is grow­ing, as it an­nounced a range of agree­ments in im­muno-on­col­o­gy and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

A service from the Financial Times